Document 0834
 DOCN  M9620834
 TI    Presence of neutralizing antibodies to heterologous human
       immunodeficiency virus type 1 isolates in sera of infected individuals
       is not predictive of rate of disease progression.
 DT    9602
 AU    Warren RQ; Wong MT; Melcher GP; Blatt SP; Zapiola I; Bouzas MB; Muchinik
       G; Anderson SA; Kennedy RC; Department of Virology and Immunology,
       Southwest Foundation for; Biomedical Research, San Antonio, Texas 78228,
       USA.
 SO    Clin Diagn Lab Immunol. 1995 Jul;2(4):400-3. Unique Identifier :
       AIDSLINE MED/96082413
 AB    These studies were undertaken to examine whether the presence of human
       immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies in sera of
       infected individuals would alter the rate of disease progression.
       HIV-1-infected individuals (n = 87) were initially examined for
       neutralizing activity in vitro against both laboratory and tissue
       culture-adapted clinical heterologous HIV-1 isolates. The neutralizing
       activities of sera were determined by a 90% or greater reduction in
       HIV-1 p24 levels in vitro. In a cross-sectional analysis of all infected
       individuals, we observed that sera from asymptomatic individuals
       neutralized a significantly greater number of heterologous HIV-1
       isolates than sera from symptomatic patients. Patients who could be
       followed up longitudinally (n = 24) were then studied to determine the
       impact of neutralizing antibodies on the rate of disease progression. We
       observed no significant difference between the numbers of HIV-1 isolates
       neutralized in vitro by sera from patients who remained clinically
       stable and by those from patients who progressed rapidly. Our data
       indicated that the presence or absence of neutralizing antibodies to
       heterologous HIV-1 isolates was not associated with the rate of disease
       progression.
 DE    Adult  Binding, Competitive/IMMUNOLOGY  Disease Progression  Female
       Human  HIV Antibodies/BIOSYNTHESIS/*BLOOD  HIV
       Infections/EPIDEMIOLOGY/*IMMUNOLOGY  HIV Seroprevalence
       HIV-1/*IMMUNOLOGY  Infant  Longitudinal Studies  Male  Support, U.S.
       Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).